We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

161 hedge funds and large institutions have $176M invested in Heron Therapeutics in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 51 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

7,109% more call options, than puts

Call options by funds: $4.61M | Put options by funds: $64K

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

4.75% less ownership

Funds ownership: 80.32% → 75.57% (-4.8%)

7% less funds holding

Funds holding: 173 → 161 (-12)

18% less repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 51

26% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 35

27% less capital invested

Capital invested by funds: $242M → $176M (-$66.6M)

Holders
161
Holders Change
-12
Holders Change %
-6.94%
% of All Funds
2.12%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
26
Increased
42
Reduced
51
Closed
35
Calls
$4.61M
Puts
$64K
Net Calls
+$4.55M
Net Calls Change
+$4.47M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.99M
2
Morgan Stanley
Morgan Stanley
New York
+$1.66M
3
SCM
Stonepine Capital Management
Oregon
+$1.13M
4
CPC
Congress Park Capital
New York
+$774K
5
QOP
Quinn Opportunity Partners
Virginia
+$616K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$2.58M
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$2.28M
3
Goldman Sachs
Goldman Sachs
New York
-$1.71M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.33M
5
N
Nuveen
North Carolina
-$1.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$1.26M +$20.3K +12,500 +2%
CM
27
CM Management
Florida
$1.07M +$324K +200,000 +40%
SCM
28
Stonepine Capital Management
Oregon
$1.07M +$1.13M +700,000 New
Goldman Sachs
29
Goldman Sachs
New York
$1M -$1.71M -1,051,992 -62%
RB
30
Richmond Brothers
Michigan
$983K +$213K +131,557 +26%
JP Morgan Chase
31
JP Morgan Chase
New York
$861K +$577K +356,053 +172%
Wellington Management Group
32
Wellington Management Group
Massachusetts
$747K -$13.1K -8,105 -2%
NAM
33
Nexpoint Asset Management
Texas
$728K – – –
QOP
34
Quinn Opportunity Partners
Virginia
$581K +$616K +380,000 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$521K -$47 -29 -0%
N
36
Nuveen
North Carolina
$481K -$1.28M -792,421 -72%
BCM
37
Bridgeway Capital Management
Texas
$459K +$486K +300,000 New
XT
38
XTX Topco
Cayman Islands
$455K -$135 -83 -0%
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$424K +$2.27K +1,398 +0.5%
JGC
40
J. Goldman & Co
New York
$413K +$438K +270,100 New
AR
41
Apeiron RIA
Texas
$402K +$30.8K +19,000 +8%
Barclays
42
Barclays
United Kingdom
$369K +$37.1K +22,891 +10%
Millennium Management
43
Millennium Management
New York
$330K -$1.17M -718,857 -77%
AQR Capital Management
44
AQR Capital Management
Connecticut
$329K -$1.11M -685,150 -76%
AllianceBernstein
45
AllianceBernstein
Tennessee
$304K – – –
Fidelity Investments
46
Fidelity Investments
Massachusetts
$294K -$389K -240,020 -56%
RhumbLine Advisers
47
RhumbLine Advisers
Massachusetts
$272K +$3.07K +1,895 +1%
UBS Group
48
UBS Group
Switzerland
$244K +$120K +74,223 +87%
Raymond James Financial
49
Raymond James Financial
Florida
$208K +$220K +135,722 New
ZDA
50
Zweig-DiMenna Associates
New York
$197K – – –
1
2
3 4 5

HRTX Hedge Fund Activity: Q4 2024 in Review

161 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2024, worth a combined $176M — down 27% from $242M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of HRTX and 26 opened new positions — a net loss of 9 holders — while 51 trimmed existing stakes and 42 added.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.99M. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.58M sold.

  • 161 institutional investors held Heron Therapeutics (HRTX) as of Q4 2024, down from 173 in Q3 2024.
  • Funds reported $176M of Heron Therapeutics stock for Q4 2024, down 27% quarter-over-quarter.
  • 26 funds opened new Heron Therapeutics positions in Q4 2024 and 35 closed out, a net change of -9 holders.
  • The largest Heron Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $4.99M added.
  • The largest Heron Therapeutics seller in Q4 2024 was Citadel Advisors, an estimated $2.58M sold.

Based on aggregated 13F filings for Q4 2024.